GnRH Analogues for the Treatment of Endometriosis-Related Pain: A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology.
PubMed 42513357 · doi:10.3390/jcm15145440
What was done
This narrative review synthesized current literature on GnRH agonists and oral antagonists for the management of endometriosis-associated pain, evaluating their biological rationale, clinical efficacy, safety profiles, and the role of adjunctive add-back therapy.
What was found
The abstract reports no numerical data or statistical measures. Qualitatively, both GnRH agonists and antagonists provided clinically significant pain relief for patients refractory to first-line treatments like oral contraceptives or progestins. Both classes induced hypoestrogenic adverse effects—particularly vasomotor symptoms and bone mineral density loss—often necessitating add-back therapy. Oral antagonists were noted to provide practical benefits, including rapid onset of action, lack of an initial flare effect, and dose-adjustable hormonal suppression.
Why it matters
This synthesis provides clinicians with a comparative overview of second-line GnRH therapies, helping guide individual treatment selection based on onset speed, reversibility, side-effect profiles, and bone health preservation.
Limits
This is an unsystematic narrative review, precluding quantitative pooling or formal risk-of-bias assessment. The abstract lacks specific study counts, patient numbers, duration of follow-up, and direct comparative effect estimates between drug classes.
Cited by
- supports GnRH antagonist medications like Orilissa and Myfembree can only be taken for up to two years because of the risk of bone mineral density loss.